New hope for dialysis patients suffering from relentless itching
NCT ID NCT04711603
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This study tested a drug called MR13A9 in 178 adults on hemodialysis who had severe itching not caused by other conditions. Participants received either the drug or a placebo for 4 weeks, followed by an open-label phase to check long-term safety. The main goal was to see if MR13A9 reduces itch intensity better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.